JBCHEPHARM vs NECLIFE: Stock Comparison
JB Chemicals & Pharmaceuticals Limited vs Nectar Lifesciences Limited
Live data: 16 July 2026, 4:08 PM IST • Source: NSE and company filings
JB Chemicals & Pharmaceuticals Limited is the larger company by market capitalisation. JB Chemicals & Pharmaceuticals Limited shows a higher ROE, a higher dividend yield and a higher ROCE, while Nectar Lifesciences Limited shows a lower P/E and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Side-by-side comparison of JB Chemicals & Pharmaceuticals Limited and Nectar Lifesciences Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | JBCHEPHARM | NECLIFE |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | JBCHEPHARM | NECLIFE |
|---|---|---|
| Live Price | ₹2,408.9 | ₹13.56 |
| Day Change | -3.87% | -5.57% |
| Volume | 47.79 L | 7 L |
| 52-Week High | ₹2,525.5 | ₹21.4 |
| 52-Week Low | ₹1,638.5 | ₹9.3 |
| Distance from 52W High | -4.62% | -36.64% |
Valuation
| Metric | JBCHEPHARM | NECLIFE |
|---|---|---|
| Market Cap | ₹38,731 Cr | ₹202 Cr |
| P/E Ratio | 54.59x | -0.8x |
| P/B Ratio | 9.31x | 0.4x |
| EPS | ₹44.49 | ₹-8.06 |
| Book Value | ₹259.05 | ₹42.63 |
| Dividend Yield | 1.19% | 0% |
Growth
| Metric | JBCHEPHARM | NECLIFE |
|---|---|---|
| Revenue Growth (TTM YoY) | -4.8% | -3.41% |
| EPS Growth (TTM YoY) | -31% | 0% |
| Qtr Sales Growth | -4.77% | -21.9% |
| Qtr Profit Growth | -17% | -2,229% |
Profitability & Leverage
| Metric | JBCHEPHARM | NECLIFE |
|---|---|---|
| ROE | 18.9% | -9.85% |
| ROCE | 25.4% | -5.36% |
| Net Margin | 17.1% | -11.28% |
| Operating Margin | 26.7% | — |
| Debt to Equity | 0x | 0x |
Shareholding
As of Mar 2026 • change vs previous quarter| Metric | JBCHEPHARM | NECLIFE |
|---|---|---|
| Promoter Holding | 48.8%▲ 48.8 pp | 51.84% |
| FII Holding | 16.33%▲ 1.45 pp | 0.5%▼ 0.1 pp |
| DII Holding | 21.38%▼ 1.98 pp | 3.74%▼ 0.27 pp |
| Public Holding | 13.48%▼ 0.74 pp | 43.89%▲ 0.37 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: JB Chemicals & Pharmaceuticals Limited and Nectar Lifesciences Limited.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.